About
About Menlo Therapeutics Inc
Menlo Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was founded in 2003 and is headquartered in Bridgewater, New Jersey.
Visit company website
5 years, 4 months ago
Menlo Therapeutics Inc is currently in a long term uptrend where the price is trading 22.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.2.
Menlo Therapeutics Inc's total revenue rose by inf% to $4M since the same quarter in the previous year.
Its net income has dropped by 7.8% to $-23M since the same quarter in the previous year.
Finally, its free cash flow fell by 54.5% to $-25M since the same quarter in the previous year.
Based on the above factors, Menlo Therapeutics Inc gets an overall score of 3/5.